Table 1. Clinical and pathological characteristics of our cohort.
| Overall | ||
| n | 639 | |
| Estrogen receptor status (%) | Neg | 117 (26.8) (*20.7) |
| Pos | 319 (73.2) (*56.4) | |
| Unknown | 130 (*22.9) | |
| Progesteron receptor status (%) | Neg | 198 (45.4) (*35) |
| Pos | 238 (54.6) (*42) | |
| Unknown | 130 (*23) | |
| HER2 status (%) | Neg | 159 (61.6) (*28.1) |
| Pos | 99 (38.4) (*17.5) | |
| Unknown | 308 (*54.4) | |
| Ki67 status (%) | Neg | 106 (42.7) (*18.7) |
| Pos | 142 (57.3) (*25.1) | |
| Unknown | 318 (*56.2) | |
| Nodal Metastases (%) | No | 31 (47.7) (*5.5) |
| Yes | 34 (52.3) (*6) | |
| Unknown | 501 (*88.5) | |
| Year of diagnosis (median [IQR]) | 1992.00 [1989.00, 1995.00] | |
| Tumor size in mm (median [IQR]) | 22.00 [15.00, 33.00] | |
| Grade (%) | 1 | 11 (11.6) (*1.9) |
| 2 | 40 (42.1) (*7.1) | |
| 3 | 41 (43.2) (*7.2) | |
| Other | 3 (3.2) (*0.5) | |
| Unknown | 471 (*83.3) | |
| TNM Stage (%) | I | 13 (20.3) (*2.3) |
| IIa | 20 (31.2) (*3.5) | |
| IIb | 13 (20.3) (*2.3) | |
| IIIa | 9 (14.1) (*1.6) | |
| IIIb | 6 (9.4) (*1.1) | |
| IV | 3 (4.7) (*0.53) | |
| Unknown | 502 (*88.7) | |
| Age of diagnosis (median [IQR]) | 56.00 [46.00, 66.00] | |
| Sampletype (%) | Normal | 73 (*11.4) |
| Tumor | 566 (*88.6) | |
| Subtype (%) | 5NP | 7 (3.5) (*1.2) |
| Basal-like | 37 (18.6) (*6.5) | |
| HER2 | 15 (7.5) (*2.7) | |
| LumA | 74 (37.2) (*13.1) | |
| LumB | 66 (33.2) (*11.7) | |
| Unknown | 367 (*64.8) |
Percentages are in brackets of known val 1.